Nanobiotix (NBTX) said late Monday it completed the dose escalation and expansion phases of a phase 1 study evaluating radiotherapy-activated NBTXR3 for patients with advanced or borderline resectable pancreatic cancer.
The study showed promising results, with a 23-month median overall survival from diagnosis in 22 patients, compared to a 19.2-month historical control at The University of Texas MD Anderson Cancer Center.
The treatment was well-tolerated, and investigators concluded that its favorable safety profile and oncologic outcomes warrant further evaluation in a randomized trial, the company said.
Following positive results, MD Anderson received US FDA clearance for an additional cohort studying NBTXR3 with chemoradiation. Recruitment for the new cohort is ongoing.
Nanobiotix anticipates that MD Anderson will present full results from the completed study phases at a medical congress in H1 2025.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。